WCLC's a heavy hit! PD-1/L1、RET、MET...... Hot...

The 2020 World Lung Cancer Congress (2020 WCLC), organized by the International Lung Cancer Research Association, has been postponed until 2021 due to the new crown outbreak and will be officially launched online this month.
with the progress of some of the heavyweight varieties, such as Sorasasib (AMG510) Registered Clinical Phase II. Data, the summary of other meetings has been made public, and today we look at some of the hot-button studies at this meeting.
PD-1/L1 inhibitor PD-1/L1 field of competition is very fierce, the domestic health care negotiations have just ended, 2021 will also usher in several products on the market, whether the price bottom line is further explored worthy of attention.
competition between the various varieties in addition to the price and adaptation has been approved, clinical data has been a crucial factor.
, on the other hand, PD-1-related specific dual resistance and joint applications with innovative targets are also on the rise.
5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in PreviouslyTreated, The results of the KEYNOTE-010 study (NCT01905657), published at this meeting of PD-L1-Positive Advanced NSCLC, showed that Pablic pearl monoanti (2 or 10 mg/kg Q3W) significantly improved OS in patients with advanced NSCLC (PD-L1 TPS≥50% and ≥1%) who had previously received treatment.
patients were randomly accepted at 1:1:1 for Pabliju monoanti (2 or 10 mg/kg Q3W) or dossy (75 mg/m2 Q3W).
35 cycles (-2 years) or until the disease progresses/unacceptable toxicity.
Eligible patients who have completed Paboliju monoantitherapy or stopped Paboliju monoantitherapy after reaching CR and received ≥6 months of treatment may receive a second course of Paboliju monoantitherapy for a period of 17 cycles (1 year) when the progression of the disease after the cessation of Paboliju monotherapy.
survival rate is assessed every 2 months after treatment.
results showed that 1033 patients (Paboli juju monoanti, 690; dorsey, 343).
as of April 8, 2020, the average (range) time from random grouping to data cutoff was 67.4 (60.0-77.9).
PD L1 TPS≥ OS and PFS were significantly better in 50% and ≥1% of patients, with 79 patients in the Pabli Pearl monoantigen group completing 35 cycles or 2 years of treatment with an ORR of 98.7% (15 CR, 63 PR).
Of the patients who completed 35 cycles or two years of Pabliju monotherapy, 61 patients (77.2%) survived (38 patients still did not have PD) and the three-year OS rate after 35 cycles or 2 years (i.e., about 5 years) was 83.0%.
21 patients received the second course of Pabliju monotherapy, and as of the data, 15 (71.4%) patients were still alive at the data cut-off.
orR was 52.4% (1 CR, 10 PR) after the start of the second course of treatment, and 6 patients received SD.
In addition to the KEYNOTE-010 study, a four-year follow-up data for the KEYNOTE-189 study was released, and 616 patients were randomly accepted for Pabli pearl monoantigen-plus-pentoplatin (n-410) or placebo-plus-methionin (n-206).
the mid-range time from randomization to data cutoff (August 28, 2020) was 46.3 (41.8-54.1) months, and 84 patients (40.8%) randomly assigned to the control group were transferred to Paboliju monodride therapy in the study.
the middle (95%CI) OS of Pablo's pearl monoantigen-resistant combined Pyme curvature platinum was 22.0 (19.5/u201224.5) months, placebo-pemetroce white The gold is 10.6 (8.7/u201213.6) months (HR, 0.60; 95%CI, 0.50\u20120.72).
3-year OS rate is 31.3% vs 17.4%.
(95%CI) PFS is 9.0 (8.1-u201210.4) months and 4.9 (4.7-u20125.5) months (HR,0.50; 95％CI,0.41\u20120.59）。
72.1% of patients in the Pabli pearl monoantigen-resistant combined Pythonser platinum group had a grade 3-u20125 AE, and the placebo combined Pythonse platinum group had 67.3%.
of the 56 patients who completed 35 cycles (2 years) of Pabliju monotherapy had an objective response (CR-6; PR-43) and 7 (12.5%) had SD.
45 patients (80.4%) survived the data cut-off (28 without PD), and the two-year OS after 35 cycles was 79.6%.
addition, there are KEYNOTE-042 studies of first-line late-stage / transfer NSCLC patients 3-year survival rate update data, etc. , limited to space, not statistics.
IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chely as First-Line Treatment in PD-L1-Selected NSCLCIII Phase IMpower110 Study (NCT02409342) primarily evaluates the therapeutic effect of first-line atilijudium in PD-L1-selected scaly or non-scale NSCLC.
IMpower110 reached its primary endpoint in OS In-Period Analysis (IA; Data Deadline: September 10, 2018).
this time, the final OS analysis results for patients with TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT were reported.
patients are eligible for PD-L1-selected (≥1% PD-L1 on TC (tumour cell) or IC (tumor-soaked immune cells, TC1/2/3 or IC1/2/3); VENTANASP142 IHC assays), IV phase NSCLC without chemotherapy, ECOG PS 0-1.
patients were randomly assigned to Arm A (atilijutin 1200 mg IV q3w) or Arm B (platinum-based chemotherapy; 4 or 6 21-day cycles) in a 1:1 ratio.
in group B, patients with non-scaly disease received cisplatin (75 mg/m2) or carptin (AUC 6) and peme curvature (500mg/m2 IV q3w), patients with scaly disease received Cisplatin (75 mg/m2) plus Gissinabin (1250 mg/m2) or Capatin (AUC 5) and Gissythabham (1000mg/m2 IV q3w).
the main OS endpoints were layered through the PD-L1 expression status of WT patients: TC3 or IC3 (≥50% TC or ≥10%IC), followed by TC2 / 3 or IC2 / 3 (≥5% TC or IC), then TC1 / 2/3 or IC1 / 2/3.
after an additional 17 months of follow-up (data cut-off date: 4 February 2020), OS in patients with TC2/3 or IC2/3-WT showed numerical benefits between groups A and B, but were not statistically significant.
in patients with TC3 or IC3-WT, exploratory OS analysis showed continued improvement in clinical significance in Arm A and B groups.
treatment-related AE (TRAE) and 3-4 levels of TRAE are 62.9% (Arm A), 85.2% (Arm B), and 14.3% (Arm A) and 44.9% (Arm B), respectively.
in the final OS analysis, IMpower110 did not show statistical significance in patients with TC2/3 or IC2/3-WT.
exploratory update analysis of patients with TC3 or IC3-WT showed that OS continued to have clinical benefits compared to chemotherapy groups.
overall safety of atezolizumab in IMpower110 is consistent with OS IA data and the use of atleticojucin in previous adaptations.
A Phase II Study of KN046 (Bispecific Anti-PD-L1/CTLA-4) in Patients (pts) with Metast Non-Small Cell Lung Cancer (NSCLC) KN046 is a new dual-specific antibody that blocks the interaction between PD-L1 and PD1 and the interaction between CTLA-4 and CD80/CD86.
the initial safety and ability of KN046 in patients with metastasis non-small cell lung cancer (NSCLC) in this multi-queue single-arm Phase II study.
late NSCLC, which was included in the progression of the disease without EGFR mutation or ALC fusion in first-line platinum chemotherapy, was not treated with any PD-(L)1 immuno checkpoint inhibitors.
KN046 (queue A, Q2W IV 3 mg/k g or queue B, 5 mg / kg) to all patients until the disease progresses, unbearable toxicity, etc.
as of 27 July 2020, there were 30 patients in Queue A and 33 cases in Queue B.
≥ treatment-related emergency adverse events (TRAEs) occurred in 21 (33.3%) patients, 16 (25.4%) in treatment-related severe adverse events (SAEs), 34 (54.0%) in immuno-related adverse events (irAEs) and 11 (17.5%) in ≥3 iraEs 11 (17.5%).
common (≥10%) TRAE is infusion-related reactions (16,25.4%), anemia (14,22.2%), rash (13,20.6%), high blood sugar (12,19.0%), liver abnormality (10,15.0%) 9%), hypothyroidism (10,15.9%), increase in alanine transaminase (8,12.7%), fatigue (8,12.7%), increase in tianmen dongeine transaminase (7,11.1%) and itching (7,11.1%).
are as secure as the two queues.
to the data cut-off date, 24 (37.5%) patients were still receiving treatment, and 39 (60.9%) were interrupted due to disease progressity (n s 27), AE (n s7), patient compliance difference (n s 4), and one death.
14 weeks (2-56 weeks) for drug exposure.
orR and DCR of Queue A and Queue B were 10.7% and 82.1%, 15.6% and 62.5%, respectively.
PFS median was 3.7 (2.9, 7.3), 3, 6 and 9 months PFS (95%CI) was 64.1% (49.4, 75.5), 36.6% (23.0, 50.4) and 34.2% (2 0.9, 47.9); 3, 6 and 9 months OS rate (95%CI) was 91.4% (80.5, 96.3), 86.9% (74.2,93.6) and 81.0% (65.8, 89.9).
in scaly NSCLC, the medium PFS was 7.3 (3.7, NE), the 3, 6 and 9-month PFS rate (95%CI) was 80.0% (54.9, 92.0), 55.9% (27.0,77.2) and 46.6% (19.0%, 70.3), 3, 6 and 9-month OS rates (95%CI) were 100.0% (100.0, 100.0), 88.2% (60.2,96.9) and 88.2% (60.2,96.9).
ret inhibitor RET highly selective inhibitors are set to break new ground in 2020, with Platini (PRalsetinib, BLU-667) and Selpercatini (LOXO-292) approved for listing, and multiple data disclosures at this session, where we have selected several studies related to patients in China or Asia for reference.
The Gene Fusion Landscape of Lung Cancer in a Chinese Retrospective Analysis presented a retrospective study on the genetic fusion of lung cancer in China.
analyzed NGS results from 12,888 lung cancer patients from January 2017 to November 2019, including 7,401 tissue samples and 5,487 plasma samples.
the fusion patterns of ARK, BCR, BRAF, EGFR, NTRK1, PDGFRB, PDGFRA, RARA, RET, and ROS1 genes.
results showed that a total of 767 (5.95%) bit fusion patients were detected, including 62% (476/767) of ALK fusion patients and 18% (137/) 767) RET fusion patients, 12% (93/767) ROS1 fusion patients, 4% (32/767) BRAF fusion patients, 1.2 NTRK1 fusion patients at 4% (11/767), PDGFRA fusion patients at 1.4% (11/767), EGFR patients at 1.2% (9/767) and PDGFRB fusion patients at 0.5% (4/767) and BCR fusion patients at 0.3% (2/767).
compared to lung cancer patients in the original queue (n s 12,888; males 7,211, females 5,677), fusion occurred mainly in women (P).